GHK-Cu (a copper-binding tripeptide) has long drawn attention for its wound-healing and tissue-remodeling properties. More recently, researchers have begun asking whether its effects extend deeper, into the chromatin landscape itself. The question is not merely whether GHK-Cu alters gene expression, but whether it does so through pathways that intersect with known longevity regulators. One such intersection sits at the crossroads of NAD+ metabolism and sirtuin activity.
Why this study
Prior work established that GHK-Cu can reset gene expression patterns toward a more youthful state, suppressing fibrosis-related genes while upregulating collagen and antioxidant pathways. But the mechanistic link to sirtuins, the NAD+-dependent deacetylases that sit at the center of caloric restriction biology, remained largely unexplored. If GHK-Cu's epigenetic effects depend on sirtuin activation, then NAD+ availability becomes a limiting factor. This study set out to test whether NAD+ supplementation amplifies GHK-Cu's transcriptional remodeling, and whether that amplification is sirtuin-dependent.
Methods
Primary human dermal fibroblasts from donors aged 60–75 were cultured to replicative senescence. Cells were treated for 72 hours with one of four conditions: GHK-Cu alone at 10 nM, nicotinamide riboside (NR, an NAD+ precursor) at 500 µM, GHK-Cu plus NR, or vehicle control. A subset of the combination group also received EX-527, a selective SIRT1 inhibitor, at 10 µM. NAD+ levels were measured by enzymatic cycling assay. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) targeted H3K9ac and H3K27ac marks. RNA-seq was performed in parallel. SIRT1 and SIRT6 protein levels were assessed by western blot.
Results
NAD+ levels rose by roughly 40–60% in NR-treated groups relative to controls. GHK-Cu alone produced a modest increase of about 15–25%. The combination pushed NAD+ up by something like 70–90%, suggesting a synergistic effect on NAD+ synthesis or salvage. ChIP-seq revealed that GHK-Cu alone reduced H3K9ac at promoter regions of pro-inflammatory genes such as IL-6 and TNF-α. Adding NR deepened these reductions by an additional 30–50%, and also broadened the set of affected loci to include genes involved in mitochondrial quality control. EX-527 blocked most of the NR-enhanced changes, indicating SIRT1 dependence. RNA-seq confirmed that the combination upregulated collagen type I and III transcripts while downregulating MMP-1 and MMP-3 more strongly than either agent alone. SIRT1 protein levels were unchanged across conditions, but SIRT6 showed a modest increase in the combination group.
Discussion , what the authors concluded
The authors propose that GHK-Cu primes chromatin for sirtuin-mediated deacetylation, but that endogenous NAD+ levels are often insufficient to support full enzymatic activity in aged cells. By supplying exogenous NAD+ precursors, the deacetylase activity of SIRT1 (and possibly SIRT6) is enhanced, allowing GHK-Cu's epigenetic program to execute more completely. They stop short of claiming a direct physical interaction between GHK-Cu and sirtuins. Instead, they frame it as a two-step process: GHK-Cu recruits remodeling complexes to specific genomic loci, and NAD+-activated sirtuins then remove the acetyl marks that maintain an aged transcriptional state. This article discusses peptides as research compounds. It is not medical advice.
Annotated critique
The study's strengths lie in its layered experimental design. Using both ChIP-seq and RNA-seq provides complementary views of chromatin state and transcriptional output. The inclusion of EX-527 strengthens the causal argument for SIRT1 involvement. However, several gaps remain. The work was done entirely in dermal fibroblasts, leaving open the question of tissue specificity. The NR concentration used (500 µM) is high relative to typical plasma levels achievable with oral supplementation, though it falls within the range used in many cell-culture studies. The GHK-Cu dose of 10 nM is on the low end of what is often used in vitro, which makes the observed synergy more striking but also raises the possibility that higher GHK-Cu concentrations might saturate the effect without NAD+ supplementation. The SIRT6 protein increase was not explored mechanistically, and SIRT6's role in the observed epigenetic changes remains speculative. The study also did not measure other NAD+-consuming enzymes such as PARPs or CD38, which could compete for the NAD+ pool and influence outcomes. A related line of inquiry involves mitochondrial peptides like MOTS-c (a 16-amino acid mitochondrial-derived peptide), which has been shown to influence nuclear gene expression through AMPK and sirtuin pathways. How Thymalin and MOTS-c may synergize for mitochondrial rejuvenation explores one such intersection, where mitochondrial signals feed back into nuclear epigenetic programs. Whether GHK-Cu and MOTS-c converge on overlapping sirtuin-dependent nodes remains an open question.
Implications and limits
If NAD+ availability truly gates GHK-Cu's epigenetic effects, then the anti-aging potential of GHK-Cu may be underestimated in studies that do not control for cellular NAD+ status. This has practical implications for experimental design: future work should consider measuring baseline NAD+ levels and possibly co-administering NAD+ precursors to see the full range of GHK-Cu's transcriptional effects. The findings also raise the possibility that other peptides with epigenetic activity, such as Cortagen (a tetrapeptide with neuroprotective properties) or Vesugen (a vascular peptide), might similarly depend on NAD+-sirtuin axis function. However, extrapolation beyond dermal fibroblasts is premature. Aging affects different tissues through distinct epigenetic landscapes, and sirtuin isoforms have tissue-specific expression patterns. The study's reliance on a single cell type and a single NAD+ precursor limits generalizability. No content in this article should be interpreted as personalised medical guidance.